SynthesisFrontiers in oncology2022

Efficacy and safety of Gemogenovatucel-T (Vigil) immunotherapy for advanced ovarian carcinoma: A systematic review and meta-analysis of randomized controlled trials.

Yixin Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.